Ventric Health Resources Hub
Your destination for evidence-driven heart failure decision support.
Our resources hub is designed to help you make informed decisions with evidence organized around real-world impact. You’ll discover peer-reviewed research, clinical validation, workflow insights and economic evidence around the questions decision-makers face.
Filter by topic or content type to quickly find the information most relevant to your role, setting and priorities. For additional information about the Vivio System, browse our FAQs.
Transforming Primary Care: Early Heart Failure Detection with the Vivio System
Join Dr. Michael Laufer as he discusses how the Ventric Health's Vivio® System is shifting heart failure detection out of the hospital and into the primary care exam room. By identifying elevated filling pressures in asymptomatic (Stage B) patients in just under 5 minutes, clinicians can initiate guideline-directed medical therapy—like SGLT2 inhibitors—and lifestyle interventions earlier than ever before.
Why Echo isn’t an Easy Answer: 2026 ESC Diagnostic Guide
This infographic details the 2026 ESC diagnosis pathway for HFpEF, stressing that a normal resting echo doesn't rule out early disease. Highlighting echo's diagnostic uncertainty, it builds a strong case for Vivio as a superior, non-invasive tool to identify Stage B heart failure, even before ESC guidelines recognize non-invasive LVEDP measurement. Source: Harefield Echocardiography
The Hidden Financial Drain of “Normal” Echoes
Relying on standard echocardiograms to detect heart failure leaves value-based care organizations financially exposed. Because standard echoes miss early-stage hemodynamic dysfunction, patients go undiagnosed until a costly crisis. Upgrading to the Vivio System for early assessment closes this diagnostic gap, enables accurate HCC coding, and protects against RADV audits.
Patient Education Toolkit – English & Spanish Materials
Use Vivio’s patient education toolkit to create a simple, consistent experience that supports informed conversations about heart failure evaluation. Available in English and Spanish, this collection of patient-facing materials explains what Vivio is, why it matters, and how it fits into the journey from concern to care in a simple, approachable way. Take a closer look at what’s available for immediate downloading.
Silent Until Severe: Are You Missing the Early Signs?
Standard diagnostic tools like NT-proBNP and resting echocardiograms consistently miss the mark when it comes to early-stage HFpEF, often producing false negatives that delay critical care. This fast-facts infographic breaks down the scale of this diagnostic gap and reveals how bringing non-invasive LVEDP measurement into the outpatient setting can help you definitively diagnose Stage B and Stage C heart failure in under five minutes.
Optimizing GDMT to Lower Heart Failure Costs
Stellus Rx details how optimizing guideline-directed medical therapy (GDMT) for heart failure dramatically improves clinical and financial outcomes. Aimed at primary care physicians in value-based care, this resource shows how integrating pharmacist-led clinical support into existing workflows helps patients stay on therapy, reducing $50,000 hospitalization risks and lowering total cost of care without adding administrative burden.
Simple Clinical Strategy Leads to Large Public Health Benefits
A recent study in the European Heart Journal highlights the benefits of starting disease-modifying therapies in community-based patients with suspected heart failure. For patients with elevated NT-proBNP, early treatment with SGLT2 inhibitors and MRAs before diagnostic echocardiography significantly reduces the 12-month risk of hospitalization or death.
Peer-Reviewed Clinical Evidence for the Vivio System
Explore peer-reviewed research and multicenter clinical studies validating the Vivio System. Learn how non-invasive brachial cuff-ECG sensing accurately detects elevated left ventricular end-diastolic pressure (LVEDP) to support earlier heart failure diagnosis and improved patient outcomes across primary care and population-health settings.
Why SGLT2 Inhibitors May Work Within Days in Heart Failure
New research may help explain why SGLT2 inhibitors can benefit people with heart failure so quickly. Researchers found that these medications activate PANK1, an enzyme that boosts energy production in heart cells—potentially improving the heart’s ability to contract and relax within days of treatment.
What JACC’s New Report Tells Us About a Widening Gap in Heart Failure Care
Heart failure mortality is rising. JACC Cardiovascular Statistics in the United States, 2026, is the American College of Cardiology’s first attempt at a comprehensive, annually recurring benchmark of U.S. cardiovascular health. It’s a sobering read. After decades of steady progress against heart disease, the report finds that gains are slowing across nearly every major condition — and in some cases, reversing outright.
Early Heart Detection: Vivio Clinician Guide
Download our Clinician Onboarding Guide to earn how to implement rapid, non-invasive LVEDP measurement at the point of care with the Vivio System. This clinician onboarding guide explores the challenges of late-stage heart failure diagnosis and how Vivio overcomes traditional limitations to accurately identify HFpEF earlier in primary care.
Webinar Recording: Heart Failure Management for PCPs
A panel of industry experts to explore diagnostic and management challenges of heart failure from a primary care perspective. This 45-minute video offers actionable insights and best practices for managing newly diagnosed Stage B and Stage C heart failure patients directly in your clinic, including effective treatment and referral options.
